INmune Bio (INmune Bio) Net Margin % : -30,028.57% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. INmune Bio's Net Income for the three months ended in Dec. 2023 was $-8.41 Mil. INmune Bio's Revenue for the three months ended in Dec. 2023 was $0.03 Mil. Therefore, INmune Bio's net margin for the quarter that ended in Dec. 2023 was -30,028.57%.

The historical rank and industry rank for INmune Bio's Net Margin % or its related term are showing as below:

INMB' s Net Margin % Range Over the Past 10 Years
Min: -109990.91 Med: -18061.22 Max: -7299.2
Current: -19360

INMB's Net Margin % is ranked worse than
93.5% of 1030 companies
in the Biotechnology industry
Industry Median: -157.59 vs INMB: -19360.00

INmune Bio Net Margin % Historical Data

The historical data trend for INmune Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Net Margin % Chart

INmune Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-109,990.91

-16,762.43

-7,299.20

-19,360.00

INmune Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-6,013.40	-17,200.00	-14,132.61	-19,913.95	-30,028.57

Competitive Comparison of INmune Bio's Net Margin %

For the Biotechnology subindustry, INmune Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where INmune Bio's Net Margin % falls into.

INmune Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

INmune Bio's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-30.008	/	0.155
	=	-19,360.00 %

INmune Bio's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-8.408	/	0.028
	=	-30,028.57 %

INmune Bio (NAS:INMB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

INmune Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of INmune Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

INmune Bio (INmune Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Executives

Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016